15+ years commercial leadership & general management in pharma & biotech
Former Amgen GM Germany/Spain/Portugal; CVP & GM, US Bone Health & Cardiology
MSc & PhD – Chemical Engineering – ETH Zurich
Wayne Paterson
Director & CEO, Anteris Technologies Ltd
Leadership roles at Roche (Korea/China) and Merck KGaA (Global CV Medicine, 2010–2012)
Jay Horton, MD
Pioneer in PCSK9 characterization and LDL-R interactions
Professor of Internal Medicine & Molecular Genetics; Chief, Digestive & Liver Diseases, UT Southwestern
George M. Tsoukas, MD, FRCPC
Associate Professor of Medicine, McGill University Health Centre
Seasoned expert in endocrinology and cardiovascular disease, and has authored numerous scientific papers
Fellow of the Royal College of Physicians of Canada and an active member of several professional societies, including the American Society for Bone and Mineral Research and the American Heart Association
Nabil G. Seidah, MC, PhD, OQ, PRSC
Discovered & cloned seven of nine proprotein convertases including PCSK9
Author of 720+ peer‑reviewed articles; numerous prestigious awards
Michael D. Shapiro, DO
Professor of Cardiology & Molecular Medicine, Wake Forest University
Research in atherosclerosis imaging, lipid disorders, PCSK9 physiology
Nicola Ferri, PhD
Professor of Pharmacology, University of Padua
Author of 190+ peer‑reviewed articles; ‘Emerging oral therapeutic strategies for inhibiting PCSK9’
Ajoy Basak, MSc, PhD, FIC
Inventor of AQR‑008; 25+ years in PCSK9 & cholesterol research
Adjunct Professor, University of Ottawa; Affiliate Investigator, Ottawa Hospital Research Institute
David M. Lubman, PhD
Professor Emeritus, University of Michigan Medical School; Director, The Lubman Lab
MS – Columbia University; PhD – Stanford University
Bruce Auerbach, MS
20+ years in pharma discovery & early clinical development; former Associate Research Fellow, Pfizer
Focus on dyslipidemia & metabolic diseases
Mary G. Sorci-Thomas, PhD
Professor of Medicine, Medical College of Wisconsin (Endocrinology, Metabolism & Clinical Nutrition)
NIH-funded 33+ years; Project Leader on NIH Program Project studying Atherosclerosis & Lipid Metabolism
Robert E. Burrier, PhD
Career technology executive in pharma research; contributed to Zetia & Vytorin programs
Experience at Schering‑Plough, Merck KGaA, Eli Lilly, GelTex, Genzyme; Postdoc – Wake Forest University
Amanuel Sima, MD
24+ years board-certified physician (Internal Medicine, Pulmonary, Critical Care)
Diplomate, American Boards of IM, Pulmonary Medicine & Critical Care Medicine
Khaled Machaca, PhD
Senior Associate Dean for Research, Innovation & Commercialization, Weill Cornell Medicine‑Qatar
Lab focuses: Ca²⁺ signaling, non‑genomic progesterone signaling, personalized medicine for monogenic disorders
